Biotech Business - August 29, 2022
Nordic Nanovector consolidates senior leadership team and restructures
The company has announced that further to the decisions to discontinue the PARADIGME study, restructure the company and appoint Carnegie Investment Bank to explore strategic options, the senior leadership team will be consolidated, and the current CEO Erik Skullerud will transition out of his role. Nordic Nanovector’s Chief Financial Officer Malene Brondberg will assume the […]
In a new job - November 8, 2021
Nordic Nanovector appoints new CMO
Nordic Nanovector has announced the appointment of Pierre Dodion as Chief Medical Officer (CMO). Dodion is taking over the role from Christine Wilkinson Blanc, who is leaving the company for personal reasons. Wilkinson Blanc will remain with the company until January 2022 to ensure a smooth transition. “We’re delighted to bring Pierre on board as […]
In a new job - September 15, 2021
Nordic Nanovector appoints new CEO
Nordic Nanovector has appointed Erik Skullerud as Chief Executive Officer (CEO). Erik Skullerud will take up the position on 20 September 2021 and will be based in the company’s office in Zug, Switzerland, splitting his time between Zug and Nordic Nanovector’s head office in Oslo. “I am very pleased that Erik has agreed to join […]
Clinical Trials - June 22, 2021
Encouraging results from Nordic Nanovector’s LYMRIT trial
Nordic Nanovector have announces initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation. The initial results from the completed Phase I study (n=16 treated with Betalutin) show that Betalutin was well tolerated, with a good safety profile consistent with […]
Clinical Trials - May 25, 2021
Preliminary results from Nordic Nanovector’s Archer-1 trial
Nordic Nanovector announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). The preliminary results show clinical activity with seven out of seven patients achieving a response, including 5 complete responses and 2 partial responses, states the company in […]
In a new job - March 28, 2021
Nordic Nanovector appoints new CEO
Nordic Nanovector has announced the appointment of Peter L. Braun as Chief Executive Officer (CEO). He took up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland. Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialization experience with innovative oncology products and deep knowledge of […]
